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OBJECTIVES: As part of the Thematic Network on the Eco-
nomic Evaluation of Healthcare Programmes and its Applica-
tions to Decision Making in Latin American Countries
(NEVALAT), funded by the European Union, we sought to iden-
tify economic studies applicable to the region. METHODS: We
searched the OHE-IFPMA Health Economic Evaluations Data-
base (HEED), which contains detailed reports on economic 
evaluations and other types of cost analysis of health care inter-
ventions. We searched for studies classiﬁed as being applicable
to any of 18 Latin American countries, as well as those cate-
gorised as relevant to “Latin America” and “South America”.
Searches were conducted in mid-2004. RESULTS: A total of 116
studies were found, the earliest from 1991 and the most recent
published in 2003. The highest number of publications in any
year was 20 for 1997. Ninety-four of the 116 studies (81%) were
applied studies, providing some original analysis of costs and
outcomes, comparative costs of alternative interventions or costs
of illness. Amongst applied studies, cost consequences analysis
was the most frequent category of evaluation (50%), followed
by cost-effectiveness analysis (26%) and cost analyses (16%).
Only four cost utility analyses and one cost beneﬁt analysis had
been performed. By disease area, nearly one third of applied
studies related to infectious and parasitic diseases (ICD-9 chapter
one). Over half of applied studies were drug evaluations, of
which one third were of general anti-infectives for systemic use
(ATC chapter J). Of the total sample of 116 studies, 54 were rel-
evant to more than one country and 62 were single country
studies. CONCLUSIONS: A number of Latin American coun-
tries are becoming interested in the use of economic evaluation
for decision making in health care. The paucity of studies iden-
tiﬁed here suggests that a substantial investment in economic
appraisal capacity is required to bring this about.
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OBJECTIVES: The present study aims to answer the following
questions: 1) Can the results of economic evaluations be con-
sidered transferable from France to the UK, and vice versa?; 2)
What are the main reasons for any lack of transferability?; 3)
What could be done, in future studies, to increase the transfer-
ability of results?; and 4) How can international databases of
economic evaluations, such as the European Network of Health
Economic Databases (EURONHEED), help the users of studies
assess the level of generalisability in ﬁndings? METHODS: Eco-
nomic evaluations covering all health technologies and involving
the UK and France were located using searches of the UK’s NHS
Economic Evaluation Databases (NHS EED) and the French
Connaissances et Décision en ÉConomie de la Santé (CODECS)
database. Studies were then analysed using an NHS
EED/CODECS-speciﬁc checklist. This approach determined the
degree to which results could be interpreted in the context of
both countries. RESULTS: The cost-effectiveness results for
France are generally more favorable than those for the UK. The
main reasons for the lack of transferability are the absence of
country-speciﬁc effectiveness data in multinational studies and
incomplete reporting regarding cost measurements. CONCLU-
SIONS: Detailed reporting of study populations, costs and effec-
tiveness data are important in assessing the transferability of the
results of studies conducted in other settings. The results are
informative for international databases such as EURONHEED
in assessing and reporting the generalisability of economic 
evaluations.
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OBJECTIVES: In economic evaluations, failure to use the best
available evidence for the estimates of clinical effect has attracted
little attention, but may lead to biases in study results. This is a
particular concern in the evaluation of pharmaceuticals, given
the industrial sponsorship in many studies. Therefore, the objec-
tive was to investigate whether economic evaluations of drug
therapies use the best available clinical effectiveness evidence,
appropriate to the population likely to receive the drug.
METHODS: A random sample of 50 economic evaluations of
drug therapies published in 2001/2002 was selected from the
NHS Economic Evaluation Database. Study design, reporting
quality and external validity of the clinical data were assessed
using methodological checklists. To judge the applicability of the
effectiveness data, participants and settings were compared with
standard clinical practice. For each therapy, alternative, high
quality sources of clinical effectiveness data were sought in the
Cochrane databases. RESULTS: Approximately half of the
studies utilised estimates of clinical effect from randomised con-
trolled trials. Quality of reporting was good, but measures of
external validity were uniformly poor. There were potential
problems with the applicability of half the studies, in particular
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